Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
CML: early-phase trial registry
4 of 7 indexed CML trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count
CML: 7 US clinical trials tracked, 4 recruiting.
CML is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Enliven Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition cml
OPEN 4 | RECR 57% | LATE 1 | EARLY 5 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)
CML lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for CML on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
CML is recruiting above its size-band peers.
4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of CML trials is spread across many organizations.
Enliven Therapeutics accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most CML trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
CML research is mostly interventional.
6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Study of Olverembatinib (HQP1351) in Patients With CP-CML
Ascentage Pharma Group
NCT06423911
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Enliven Therapeutics
NCT05304377
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
NCT06047886
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
NCT06131801
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05823571
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
National Cancer Institute (NCI)
NCT00013533
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
Abramson Cancer Center at Penn Medicine
NCT00780104
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on CML records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on CML trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this CML page
7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 CML trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Enliven Therapeutics sponsors the most CML trials on record, review their full trial history before evaluating a specific study. See Enliven Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This CML condition card totals 7 registered trials; most-linked intervention Rapamycin + MEC; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.